Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBITDA (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBITDA for 7 consecutive years, with $244.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 367.54% to $244.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$79.6 million through Dec 2025, up 78.88% year-over-year, with the annual reading at -$79.6 million for FY2025, 78.88% up from the prior year.
  • EBITDA for Q4 2025 was $244.6 million at Beam Therapeutics, up from -$111.9 million in the prior quarter.
  • The five-year high for EBITDA was $244.6 million in Q4 2025, with the low at -$201.6 million in Q1 2021.
  • Average EBITDA over 5 years is -$62.4 million, with a median of -$91.3 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 554.08% in 2021, then skyrocketed 502.78% in 2023.
  • Over 5 years, EBITDA stood at -$64.8 million in 2021, then soared by 44.26% to -$36.1 million in 2022, then surged by 502.78% to $145.4 million in 2023, then plummeted by 162.87% to -$91.4 million in 2024, then skyrocketed by 367.54% to $244.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $244.6 million, -$111.9 million, and -$102.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.